William Blair analyst Sami Corwin has maintained their bullish stance on ZVRA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors related to Zevra Therapeutics’ strategic advancements and market potential. The recent submission of a marketing authorization application for Miplyffa to the European Medicines Agency is a significant step forward, aligning with the company’s timeline and indicating potential revenue contributions by the end of 2026.
Furthermore, the strong launch of Miplyffa in the U.S. and the company’s success in converting expanded access program patients to commercial product sales suggest a promising outlook for similar success in Europe. The presence of miglustat as an approved treatment for Niemann-Pick disease type C in the EU is expected to aid in the diagnosis and adoption of Miplyffa, enhancing its market penetration. Additionally, the commercialization of Miplyffa outside the U.S. presents opportunities for business development, supporting a positive long-term growth trajectory for Zevra.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.